SHENZHEN IONOVA LIFE SCIENCE CO., LTD., September 23, 2022 – IONOVA, a clinical-stage biotech company, based in the Guangdong-Hong Kong-Macao Greater Bay Area and with focus on discovery and development of novel medicines for cancer treatment, announces today that Dr. Chang Bai, PhD is appointed Chief Scientific Officer (CSO).
Dr. Yongkui Sun, chairman of the board and CEO of IONOVA, and a member of the US National Academy of Engineering, commented, “Dr. Bai has over 20 years of experience in the field of innovative medicines, and has extensive experience in oncology immunology and targeted drug development management at leading overseas and domestic pharmaceutical companies. We are fortunate to bring Dr. Bai on board IONOVA to lead the global development strategy and execution of IONOVA innovative drug development pipeline. We believe that he will lead our R&D programs into a new phase of development”.
Dr. Chang Bai stated, “It is a great pleasure to take this exciting opportunity to contribute to global innovative drug development and bring benefits to cancer patients worldwide together with the experienced team at IONOVA”.
